Colchicine Injection

03 March 2008

Products Affected - Description

Colchicine 0.5 mg/mL solution for injection, Bedford - discontinued
2 mL vials, package of 10 (NDC 55390-0605-02)

Reason for the Shortage

• The FDA is taking enforcement action against this unapproved drug. Companies have 30 days from February 6th to stop manufacturing colchicine injection and 180 days to stop shipping the product.¹
• Oral colchicine products are not affected by this enforcement action.¹

Estimated Resupply Dates

Bedford has discontinued colchicine injection.²

Related Shortages

• Alendronate Sodium Tablets— Resolved
• Colchicine Tablets
• Cyclosporine Injection— Resolved
• Dexrazoxane Injection
• Isosulfan Blue Injection— Resolved
• Leucovorin Injection— Resolved
• Methylene Blue Injection— Resolved
• Metyrosine Capsules— Resolved
• Muromonab-CD3 Solution for Injection— Resolved
• Pralidoxime Chloride Injection— Resolved
• Pralidoxime Injection— Resolved
• Sodium Fluoride Chewable Tablets

1. U.S. Food and Drug Administration. FDA Takes Action to Stop the Marketing of Unapproved Injectable Drugs Containing Colchicine. Accessed June 24, 2009.
2. Bedford Laboratories. Product discontinuations, written communication. February 25, 2008.

Updated

March 3, 2008; February 6, 2008; Copyright 2008, University of Utah, Drug Information Service

Back to Drug Shortage Product Bulletins